SANDOZ RIOCIGUAT DIN 02533618
Health Canada record
| Active ingredient(s) | RIOCIGUAT 2.5 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | C02KX05 RIOCIGUAT |
| Original market date | 29-Apr-2024 |
| Current status date | 29-Apr-2024 |
| Source | Health Canada DPD |
Establishment licence of the holder
Sandoz Canada Incorporated — licence 101370, currently licensed, last inspection rating C (2025-02-25).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing RIOCIGUAT
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02412764 | ADEMPAS | BAYER INC | Tablet | RIOCIGUAT 0.5 MG | Marketed |
| 02412772 | ADEMPAS | BAYER INC | Tablet | RIOCIGUAT 1 MG | Marketed |
| 02412799 | ADEMPAS | BAYER INC | Tablet | RIOCIGUAT 1.5 MG | Marketed |
| 02412802 | ADEMPAS | BAYER INC | Tablet | RIOCIGUAT 2 MG | Marketed |
| 02412810 | ADEMPAS | BAYER INC | Tablet | RIOCIGUAT 2.5 MG | Marketed |
| 02533545 | SANDOZ RIOCIGUAT | SANDOZ CANADA INCORPORATED | Tablet | RIOCIGUAT 0.5 MG | Marketed |
| 02533561 | SANDOZ RIOCIGUAT | SANDOZ CANADA INCORPORATED | Tablet | RIOCIGUAT 1 MG | Marketed |
| 02533588 | SANDOZ RIOCIGUAT | SANDOZ CANADA INCORPORATED | Tablet | RIOCIGUAT 1.5 MG | Marketed |
| 02533596 | SANDOZ RIOCIGUAT | SANDOZ CANADA INCORPORATED | Tablet | RIOCIGUAT 2 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 33002 | 2024-04-02 | Abbreviated New Drug Submission (ANDS) |
International API supply for RIOCIGUAT
1 valid EDQM Certificates of Suitability from 1 holders. 7 active FDA Drug Master Files.
Request a quote for SANDOZ RIOCIGUAT